Biogen Idec and Acorda have signed an exclusive collaboration and license agreement to develop and commercialize Fampridine-SR, a multiple sclerosis (MS) therapy, in markets outside the US. Fampridine-SR
MDS has completed the divestiture of its phase II-IV operations to INC Research. Under the terms of the agreement, INC Research has acquired MDS Pharma Services’ phase II-IV
Sepracor has completed the analysis and validation of the preliminary results of a phase II, 514-patient study. It evaluated the efficacy and safety of SEP-225289 for the treatment
Shire has announced the results of Phase 3b study of Vyvanse (lisdexamfetamine dimesylate) CII that showed significant efficacy at 14 hours after administration during a simulated workplace environment
CombinatoRx and Neuromed have entered into a merger agreement under which the companies will merge in all-stock transaction. Under the terms of the agreement, CombinatoRx is expected to
Board of Directors of Dow has approved a restructuring plan which calls for the shutdown of a number of manufacturing assets, including ethylene and ethylene-derivative assets in its
Schering-Plough has announced the results from the Phase III Engage clinical trial demonstrating that a single injection of corifollitropin alfa, achieved similar efficacy to recombinant follicle stimulating hormone
BioSante and Cell Genesys have entered into a merger agreement, under which the companies will merge in an all-stock transaction, with BioSante as the surviving company. Under the
Vical’s vaccine has showed preclinical results with 100% response against A/H1N1 pandemic influenza (swine flu), the company claims. The study enrolled mice and rabbits, where the subjects were
Prolor has received two new patents, 7553940 and 7553941, from the US Patent and Trademark Office (PTO), for its long-acting CTP-enhanced human growthhormone (hGH-CTP) and human erythropoietin (EPO-CTP).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.